. Author manuscript; available in PMC: 2016 Jan 1.

Published in final edited form as: Future Oncol. 2015 Mar;11(5):865–878. doi: 10.2217/fon.14.312

Table 1. The key targets of various agents in non-small-cell lung cancer in clinical phases of development.

Target proteins/receptors	Agents approved/under investigation for NSCLCs
EGFRs	Lapatinib^†, afatinib (BIBW2992)^†, dacomitinib (PF00299804), CO-1686, AZD9291, pertuzumab
mTOR	Sirolimus, everolimus, temsirolimus
BRAF	Dabrafenib (GSK2118436), vemurafenib (PLX4032), LGX818
MAPK	Trametenib (GSK1120212), selumetinib (AZD6244), GDC-0973
c-MET	EMD1214063, INC280, cabozantinib (XL184), tivantinib (ARQ197), foretinib (GSK1363089), onartuzumab (OAM4558g)
FGFR/VEGFR	Cediranib, nintedanib (BIBF 1120), pazopanib^†, ponatinib^† [14]
DDR2/Bcr-Abl	Dasatinib, sorafenib, ponatinib
PIK3CA	PF-4989216
AKT	MK2206, GDC0068, AZD5363
ALK	Crizotinib (PF-02341066), LDK378, AP26113, CH5424802
RET	XL-184, sorafenib

^†

US FDA-approved drugs; for more information see [15].

EGFR: EGF receptor; FGFR: FGF receptor; NSCLC: Non-small-cell lung cancer; VEGFR: VEGF receptor.